In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Health News - redOrbit
Links shared publicly online about this topic.
- 743total visits
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Health News - redOrbit
NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
View full resource at redorbit.com
Tags: Arthritis, Rheumatoid Arthritis, Phase 3 Clinical Trial, Healthy Living, Pfizer, News
Most Recently Shared on November 7, 2010 at 11:23 pm By:
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Si... http://bit.ly/bHHxot
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Nov 7, 2010
pfizer.mediaroom.com — “In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Nov 7, 2010” View full resource at pfizer.mediaroom.com
Most Recently Shared on November 7, 2010 at 10:08 pm By:
Press Release: In First Phase 3 Trial...http://bit.ly/c9aVVz
Advertisement
